



January 8, 2020

The Manager Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The Manager Listing
The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Sirs,

Sub: Intimation of Appointment of Chief Executive Officer & Managing Director of the Company

This is to inform you that the Board of Directors of the Company in their meeting held today have approved the following:

- 1) Appointment of Dr. R Ananthanarayanan (DIN: 02231540) as Chief Executive Officer & Managing Director of the Company effective January 9, 2020, for a period of 5 years, subject to approval of the Members of the Company. Further, he is also appointed as Key Managerial Personnel of the Company effective January 9, 2020.

Disclosure under Regulation 30 of the SEBI Listing Regulations for the said appointment is enclosed as Annexure.

- 2) Re-designation of Mr. Arun Kumar (DIN: 00084845) as **Executive Director** effective January 9, 2020.

Request you to kindly take the above on record.

Thanks & Regards,
For Strides Pharma Science Limited

Manjula Ramamurthy
Company Secretary



Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

**Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Appointment of Dr. R. Ananthanarayanan as Chief Executive Officer and Managing
Director w.e.f. January 9, 2020**

#	Particulars	Remarks
1.	Reason for change viz., appointment or otherwise	Appointment
2.	Date of appointment and term of appointment	Dr. R Ananthanarayanan is appointed for a period of 5 years w.e.f January 9, 2020, subject to approval of the Members of the Company.
3.	Brief Profile	<p>Dr. R Ananthanarayanan brings with him over three decades of top pedigree global pharmaceutical experience across both the technical and commercial functions. Until recently, Ananth was the Global Chief Operating Officer at Cipla Limited, where he was responsible for the company's generics business in regulated markets and branded generics in emerging markets. He was also driving their API business, biosimilars, complex drug-device combinations, including 505(b)(2) products.</p> <p>Prior to Cipla, Ananth was the President & CEO of Global APIs, Biologics, & Medis Generics B2B division at Teva Pharmaceutical Industries Ltd in the US, managing multi-billion P&L responsibility. He has also held leadership roles at Dr. Reddy's Laboratories, Piramal Healthcare (Formerly Nicholas Piramal), Galpharm International, UK (Acquired by Perrigo Group), and Zydus Cadila.</p> <p>Ananth is a Graduate in Pharmaceutical Sciences and earned his Ph.D. in Pharmaceutical Technology from the University of Mumbai, India. He has also been a member of the Board of Advisors at the School of Pharmacy and Health Sciences at Fairleigh Dickinson University, New Jersey.</p>
4.	Disclosure of relationships between directors	Dr. R. Ananthanarayanan is not related to any other Director of the Company.

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com